Chemed (CHE) Q3 2026 Earnings Call Transcript
Chemed (CHE) reported Q3 2026 earnings with total revenue up 10.6% and adjusted EPS up 28.1% YoY. VITAS saw 12.2% revenue growth, while Roto Rooter grew 7.5%. Roto Rooter's margins declined due to higher marketing costs and fuel expenses, but acquisitions are expected to drive long-term growth. The company has $229M in cash flow from operations, enabling strategic acquisitions and share repurchases.
How this was made
The 30-second read
Why it matters
The strong revenue and EPS growth, combined with robust cash flow and resolved Medicare cap issues, provide a clear catalyst for stock appreciation.
Market read
Chemed's earnings beat and cash generation are likely to drive positive sentiment in the healthcare services sector.
What to watch
Potential future Medicare cap constraints and higher marketing spend may impact profitability.
Background
Chemed Corp (CHE) released its Q3 2026 earnings call transcript, detailing financial performance across its VITAS and Roto Rooter segments.
Ticker impact
Chemed reported Q3 2026 revenue up 10.6% and adjusted diluted EPS up 28.1% versus the prior year, with strong cash flow and no Medicare cap limitation.
likely upward pressure as the market prices in better-than-expected earnings and cash flow
Revenue and EPS growth exceed prior year, Medicare cap issues resolved, and cash flow exceeds $229M, indicating improved fundamentals.
Market effects
Highlights strength in healthcare services and home health sectors, potentially boosting peers.
U.S. market focus, especially healthcare service stocks.
Moderate, as Chemed's performance may influence global healthcare service investors.
Counterpoint
Margin pressure from low-margin franchise acquisitions could offset earnings upside.
Key entities
- CompanyChemed Corp
U.S.-listed provider of home health and specialty services.
